ClinicalTrials.gg
RecruitingNCT05998759Updated May 6, 2025

Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

A Phase 2 interventional study of Telitacicept and Placebo in Connective Tissue Diseases and Thrombocytopenia, sponsored by Beijing Hospital. Recruiting at 23 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by Beijing Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
296
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 27 studies in Connective Tissue Diseases with a site in China — 13 open to participants now, 18 under way, 7 of them phase 3. Connective Tissue Diseases · China.

Planned enrollment
10th of 22
296 · median 224
Started
2023
with 4 others
Phase 2
5 of 27
2 open now
Primary completion
2025-12
later than 5 of 17 live
Registered
18th of 27
by date
Lead sponsor
1 of 27
Beijing Hospital

Among the 27 studies in Connective Tissue Diseases with a site in China, this one is the 10th largest by planned enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2023, is one of 5 in phase 2, reaches primary completion later than 5 of the 17 other live ones, and was the 18th registered.

Connective Tissue Diseases

192 studies on the registry are indexed under Connective Tissue Diseases; 56 are open to participants now.

Browse Connective Tissue Diseases studies →

Open to participants now

13 of the 27 studies in Connective Tissue Diseases with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Connective Tissue Diseases studies recruiting now, 30 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Connective Tissue Diseases with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of Telitacicept for the treatment of connective tissue disease-associated thrombocytopenia.

Read the detailed description

In this randomized, double-blind placebo-controlled study, the investigators aim to evaluate the efficacy and safety of Telitacicept for the treatment of connective tissue disease-associated thrombocytopenia. After screening, eligible participants will be randomized at a 1: 1 ratio to receive either subcutaneous Telitacicept 160 mg or placebo once a week for 24 weeks. The background standard therapy is maintained stable during the whole treatment period.

03

Conditions studied

  • Connective Tissue Diseases
  • Thrombocytopenia

Keywords

  • Connective Tissue Diseases
  • Thrombocytopenia
  • biological agents
  • B cell
  • targeted therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have been diagnosed with connective tissue disease (CTD)-associated thrombocytopenia. And CTD includes primary Sjögren syndrome (according to the 2002 American College of Rheumatology (ACR)/ European League against Rheumatism (EULAR) classification criteria), systemic lupus erythematosus (SLE, according to the 1997 or the 2009 ACR classification criteria), and undifferentiated connective tissue disease (according to the 1999 international classification criteria)
  • thrombocytopenia defined as:

Either: Failure to maintain sustained remission after treatment by and at least one (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate, leflunomide and hydroxychloroquine, et al.) Or: Relapse during oral glucocorticoid tapering or after withdrawal

  • 50×10\^9/L>
  • anti-nuclear antibody (ANA) positive (≥1:80, any karyotype) detected in the laboratory of each research center
  • Standard therapy should be maintained stable for at least 14 days prior to the first dose of the experimental drug or placebo. Standard therapy refers to the following treatment (monotherapy or in combination): glucocorticoid, hydroxychloroquine, and other immunosuppressants (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate and leflunomide, et al.)
  • Signed form, willing or able to participate in all required study evaluations and procedures

Exclusion criteria

Exclusion Criteria:

  • Vital organ lethal bleeding (including but not limited to central nervous system bleeding, digestive tract bleeding) at screening, or intracranial bleeding 6 months prior to screening
  • Antiphospholipid syndrome, thrombotic thrombocytopenia purpura, hemolytic uremic syndrome, or thrombocytopenia secondary to other causes (such as sepsis, Epstein-Barr virus infection, cytomegalovirus infection, Corona Virus Disease-19 (COVID-19) infection, drugs, etc.)
  • Hematopoietic system disorders, such as myelodysplastic syndrome, paroxysmal sleep hemoglobinuria, aplastic anemia, leukemia, lymphoma, myelofibrosis and so on
  • Severe cardiovascular system disease, including: unstable or uncontrollable disease or condition affecting the function of the heart (such as angina pectoris, congestive heart failure, uncontrolled hypertension or arrhythmia)
  • Arteriovenous thromboembolism events
  • Receiving antiplatelet or anticoagulant therapy at screening
  • changes
  • corrected Q-T interval ()>450ms for male, QTc>470ms for female
  • Severe pulmonary disease, including: unstable or uncontrollable disease or condition affecting respiratory function [e.g., diffuse alveolar hemorrhage, severe pulmonary hypertension, severe pulmonary interstitial disease (peripheral blood oxygen saturation \<92% at rest without oxygen, or forced vital capacity (FVC)\<50%, or carbon monoxide diffusing capacity (DLCO)\<50%)]
  • Severe kidney disease, including: severe lupus nephritis (urinary protein > 6 g/24 hours or endogenous \< 30 ml /min) 8 weeks prior to randomization, active nephritis requiring current protocol disallowed drugs, severe renal insufficiency requiring hemodialysis or prednisone ≥100mg/ day (or equivalent) for ≥14 days
  • SLE or non-SLE related central nervous system disease (including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident, encephalitis, central nervous system vasculitis) 8 weeks prior to randomization
  • Active hepatitis, a history of severe liver disease. Subjects positive for surface antigen (HBsAg) or antibodies to virus are excluded. As for subjects with antibodies to hepatitis B core antigen (HBcAb), further hepatitis B virus (HBV)-DNA should be tested. If HBV-DNA is negative, subjects could be enrolled; otherwise, subjects should be excluded
  • Abnormal laboratory results (including but not limited to: (ALT) or aspertate aminotransferase (AST)≥3× (upper limit of normal), white blood cell count \<1.5×10\^9/L)
  • Subjects with known active infections (e.g., shingles, COVID-19, , active tuberculosis, etc.), and active or recurrent gastrointestinal ulcers
  • Pregnant or lactating women, and subjects with a during plan during the trial
  • Allergic reaction: history of allergic reactions to human biological products
  • Treatment with B cell-targeting agents such as Rituximab or Epratuzumab or Belimumab six months prior to randomization
  • Treatment with tumor necrosis factor (TNF) inhibitors or TNF-receptor blockers six months prior to randomization
  • Participating in clinical trial 28 days or 5 drug half-lives of the agents prior to randomization
  • Received 28 days prior to randomization
  • Treatment with unstable dosage of thrombopoietin receptor agonists such as Eltrombopag or Romiplostim 14 days prior to randomization
  • Subjects with depression or suicidal thoughts
  • Previous treatment with telitacicept
  • B cell targeting drug therapy is not tolerated or responsive
  • Investigator considers candidates not appropriating for the study
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
296 participants (estimated)

Study arms

  • Experimental
    Telitacicept plus standard therapy

    Telitacicept (160mg ih qw for 24 weeks) combined with standard therapy. Standard therapy refers to the following treatment (monotherapy or in combination): glucocorticoid, hydroxychloroquine, and other immunosuppressants (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate and leflunomide, et al.).

    Biological: Telitacicept

  • Placebo comparator
    Placebo plus standard therapy

    Placebo combined with standard therapy. Standard therapy refers to the following treatment (monotherapy or in combination): glucocorticoid, hydroxychloroquine, and other immunosuppressants (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate and leflunomide, et al.).

    Drug: Placebo

Interventions

  • BiologicalTelitacicept

    subcutaneous telitacicept 160 mg weekly for 24 weeks.

    Also known as: recombinant human B lymphocyte stimulating factor receptor-Fc fusion protein, Recombinant Human B Lymphocyte(RC18), Tai'ai®

  • DrugPlacebo

    subcutaneous placebo weekly for 24 weeks.

    Also known as: Placebo control, control

06

What researchers measure

Primary outcomes

  1. Overall response (CR + PR) rate

    Response is deemed as complete (CR) if the platelet (PLT) count is ≥ 100×10\^9/L, partial (PR) if the platelet count ranges from 50×10\^9/L to 100×10\^9/L and at least doubled from baseline. No active bleeding is allowed in participants classified as CR or PR.

    Time frame: at week 24

Secondary outcomes

  1. Overall response (CR + PR) rate

    Response is deemed as complete (CR) if the platelet count is ≥ 100×10\^9/L, partial (PR) if the platelet count ranges from 50×10\^9/L to 100×10\^9/L and at least doubled from baseline. No active bleeding is allowed in participants classified as CR or PR.

    Time frame: at week 12

  2. Rescue treatment rate

    Rescue treatment is initiated if the platelet count is \<10×10\^9/L, or the participant is with active bleeding, or based on the investigator's judgement when the platelet count ranges from 10×10\^9/L to 30×10\^9/L.

    Time frame: at week 24

  3. Time to rescue treatment

    Time to rescue treatment refers to period duration from the initiation of Telitacicept or placebo (day 1) to rescue treatment.

    Time frame: at week 24

  4. Relapse rate

    No response refers to the platelet count is \< 50×10\^9/L, or increases for less than 1-fold from baseline, or with active central nervous system or digestive tract bleeding, or rescue treatment is initiated. Relapse is defined as no response recurring after a complete or partial response lasting for at least 7 days with treatment.

    Time frame: at week 24

  5. Time to relapse

    Time to relapse refers to period duration from the initiation of Telitacicept or placebo (day 1) to relapse.

    Time frame: at week 24

  6. treatment related adverse event

    According to the NCI CTCAE 5.0

    Time frame: at week 24

  7. treatment related severe adverse event

    According to the NCI CTCAE 5.0

    Time frame: at week 24

  8. bleeding scale

    According to the ITP bleeding scale (IBLS). The IBLS comprises of 11 grades from 0 (none) to 2 (marked bleeding) by history over the previous week or by exam; 2 being worse. These 11 grades include: skin by physical exam, oral by physical exam, skin by history, oral by history, epistaxis, gastrointestinal, urinary, gynecological, pulmonary, intracranial hemorrhage, and subconjunctival hemorrhage.

    Time frame: at week 24

Other outcomes

  1. life quality 1

    According to the ITP Patient Assessment Questionnaire™ (ITP-PAQ™) score. The ITP-PAQ™ is a disease-specific instrument that was designed to measure the Quality of Life (QoL) of adult patients with immune thrombocytopenia. The items employ a 4-week recall with responses recorded on 4-, 5- or 7-point Likert scales. All item scores are transformed to a 0 to 100 continuum where higher scores represent better QoL and are weighted equally to derive the scale scores.

    Time frame: at week 24

  2. life quality 2

    According to the FACT-Th6 score. The Functional Assessment of Cancer Therapy-Thrombocytopenia (FACT-Th6) consists of 6 questions in which patients rate (0-4) their general degree of worry related to bleeding and bruising, and resulting activity impairment and frustration. Items were reverse-scored as necessary such that higher scores represent higher Health-related quality of life (HRQoL). Total scores ranged from 0 to 24. Recall period is previous 7 days.

    Time frame: at week 24

  3. Absolute change rate from baseline in serum immunoglobulin G (IgG)

    (serum IgG level at week 24-serum IgG level at baseline)/ serum IgG level at baseline

    Time frame: at week 24

  4. Absolute change rate from baseline in serum immunoglobulin M (IgM)

    (serum IgM level at week 24-serum IgM level at baseline)/ serum IgM level at baseline

    Time frame: at week 24

  5. Absolute change rate from baseline in serum immunoglobulin A (IgA)

    (serum IgA level at week 24-serum IgA level at baseline)/ serum IgA level at baseline

    Time frame: at week 24

  6. Absolute change rate from baseline in serum C3

    (serum C3 level at week 24-serum C3 level at baseline)/ serum C3 level at baseline

    Time frame: at week 24

  7. Absolute change rate from baseline in serum C4

    (serum C4 level at week 24-serum C4 level at baseline)/ serum C4 level at baseline

    Time frame: at week 24

  8. Absolute change rate from baseline in serum anti-platelet antibody

    (serum anti-platelet antibody level at week 24-serum anti-platelet antibody level at baseline)/ serum anti-platelet antibody level at baseline

    Time frame: at week 24

  9. Absolute change rate from baseline in serum Blys

    (serum Blys level at week 24-serum Blys level at baseline)/ serum Blys level at baseline. Blys is short for B lymphocyte stimulator.

    Time frame: at week 24

  10. Absolute change rate from baseline in serum APRIL

    (serum APRIL level at week 24-serum APRIL level at baseline)/ serum APRIL level at baseline. APRIL is short for a proliferation-inducing ligand.

    Time frame: at week 24

  11. Absolute change rate from baseline in peripheral naive B cell count

    (peripheral naive B cell count at week 24-peripheral naive B cell count at baseline)/ peripheral naive B cell count at baseline.

    Time frame: at week 24

  12. Absolute change rate from baseline in peripheral plasma cell count

    (peripheral plasma cell count at week 24-peripheral plasma cell count at baseline)/ peripheral plasma cell count at baseline.

    Time frame: at week 24

  13. Absolute change rate from baseline in peripheral plasmablast count

    (peripheral plasmablast count at week 24-peripheral plasmablast count at baseline)/ peripheral plasmablast count at baseline.

    Time frame: at week 24

07

Study locations

23 of 23 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2025, 24 months after the start.

Of 14 phase 2 interventional studies under Connective Tissue Diseases, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2023
First posted
Aug 21, 2023
StartActual
Dec 2, 2023
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05998759
Lead sponsor
Beijing Hospital
Collaborators
The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Peking University People's Hospital, Peking University Third Hospital, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, China, Second Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The Affiliated Hospital of Inner Mongolia Medical University, First Hospital of China Medical University, Shandong Provincial Hospital, Changhai Hospital, RenJi Hospital, Shanxi Bethune Hospital, West China Hospital, Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The First People's Hospital of Yunnan
Responsible party
Yongjing Cheng (Professor, Beijing Hospital) — Principal investigator
First posted
Aug 21, 2023
Start date
Dec 2, 2023
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
May 6, 2025

Study contacts

Xuan Zhang, MD.
Contact
zxpumch2003@sina.com
+86-01085136736
Yongjing Cheng, MD.
Contact
chengyongjing3427@njhmoh.cn
+86-01085136736
Xuan Zhang, MD.
study chair · Beijing Hospital
Yongjing Cheng, MD.
study chair · Beijing Hospital
Shengqian Xu, MD.
principal investigator · The First Affiliated Hospital of Anhui Medical Hospital
Zhu Chen, MD.
principal investigator · The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)
Jing He, MD.
principal investigator · Peking University People's Hospital
Rong Mu, MD.
principal investigator · Peking University Third Hospital
Niansheng Yang, MD.
principal investigator · First Affiliated Hospital, Sun Yat-Sen University
Yang Li, MD.
principal investigator · Guangdong Provincial People's Hospital
Guanmin Gao, MD.
principal investigator · The First Affiliated Hospital of Zhengzhou University
Anbin Huang, MD.
principal investigator · Wuhan Union Hospital, China
Fen Li, MD.
principal investigator · Second Xiangya Hospital of Central South University
Hui Luo, MD.
principal investigator · Xiangya Hospital of Central South University
Hongbin Li, MD.
principal investigator · The Affiliated Hospital of Inner Mongolia Medical University
Pinting Yang, MD.
principal investigator · First Hospital of China Medical University
Hongsheng Sun, MD.
principal investigator · Shandong Provincial Hospital
Dongbao Zhao, MD.
principal investigator · Changhai Hospital
Sheng Chen, MD.
principal investigator · RenJi Hospital
Liyun Zhang, MD.
principal investigator · Shanxi Bethune Hospital
Qibing Xie, MD.
principal investigator · West China Hospital
Lei Zhang, MD.
principal investigator · Institute of Hematology & Blood Diseases Hospital, China
Wufang Qi, MD.
principal investigator · Tianjin First Central Hospital
Wei Wei, MD.
principal investigator · Tianjin Medical University General Hospital
Lijun Wu, MD.
principal investigator · People's Hospital of Xinjiang Uygur Autonomous Region
Qin Li, MD.
principal investigator · The First People's Hospital of Yunnan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion